MBX Biosciences reveals 2026 drug milestones at J.P. Morgan Healthcare Conference

MBX Biosciences will outline its clinical progress and financial position at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company is preparing for key milestones across multiple drug development programs, including treatments for rare metabolic disorders and obesity. With strong cash reserves and several trials advancing, the firm expects to expand its pipeline in the coming year. The company’s Phase 2 Avail trial for canvuparatide, a once-weekly treatment for chronic hypoparathyroidism, has already met its primary goal. High responder rates confirmed its clinical potential. Full 12-week results and one-year follow-up data will be presented at a medical conference in Q2 2026. Regulatory discussions are also underway. An FDA End-of-Phase 2 meeting is scheduled for Q1 2026 to plan the Phase 3 confirmatory trial, set to start in Q3 2026. Another key program, the Phase 2a STEADY trial of imapextide for post-bariatric hypoglycemia, will report findings in Q2 2026. The drug is designed as a once-weekly injection. In obesity, MBX Biosciences plans to introduce two new once-monthly candidates in 2026. An amycretin prodrug nomination is expected in Q2, followed by a GLP-1/GIP/GCGR prodrug in Q3. Meanwhile, MBX 4291, a GLP-1/GIP co-agonist prodrug for potential once-monthly use, continues Phase 1 testing. Data from its 12-week multiple ascending dose study should arrive in Q4 2026. Financially, the company held approximately $373.7 million in cash and marketable securities as of December 31, 2025. This funding is projected to support operations into 2029. MBX Biosciences enters 2026 with a clear roadmap for its clinical programs. Trial results, regulatory meetings, and new drug nominations will shape the year ahead. The company’s financial position provides a stable foundation for its planned expansion into obesity treatments and rare disease therapies.